Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Jan 31
Have your own idea? Try our Stock Screener
Swedish (OMX) Biotech Industry Analysis
UpdatedFeb 01, 2025
DataAggregated Company Financials
Companies61
- 7D1.5%
- 3M4.4%
- 1Y18.9%
- YTD1.0%
Over the last 7 days, the Biotech industry has risen 1.5%, driven by gains from Swedish Orphan Biovitrum of 1.1%. This means that the industry has gained 19% over the past year. Earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 01 Feb 2025 | SEK 225.7b | SEK 33.1b | -SEK 85,147,513.07 | 59x | -2650.2x | 6.8x |
| Mon, 30 Dec 2024 | SEK 220.0b | SEK 33.0b | -SEK 4,422,835,749.94 | 160.2x | -49.7x | 6.7x |
| Wed, 27 Nov 2024 | SEK 211.5b | SEK 33.1b | -SEK 4,545,138,017.03 | 149.9x | -46.5x | 6.4x |
| Fri, 25 Oct 2024 | SEK 220.5b | SEK 33.2b | -SEK 4,240,570,065.50 | 32.9x | -52x | 6.6x |
| Sun, 22 Sep 2024 | SEK 214.8b | SEK 31.5b | -SEK 5,544,590,338.58 | 51.2x | -38.7x | 6.8x |
| Tue, 20 Aug 2024 | SEK 208.1b | SEK 31.4b | -SEK 5,668,341,344.97 | 49.8x | -36.7x | 6.6x |
| Thu, 18 Jul 2024 | SEK 202.6b | SEK 31.2b | -SEK 5,482,302,154.51 | 43.4x | -36.9x | 6.5x |
| Sat, 15 Jun 2024 | SEK 191.5b | SEK 30.6b | -SEK 5,486,366,869.28 | 38.2x | -34.9x | 6.3x |
| Mon, 13 May 2024 | SEK 189.2b | SEK 31.0b | -SEK 5,215,674,476.48 | 45.7x | -36.3x | 6.1x |
| Wed, 10 Apr 2024 | SEK 182.7b | SEK 29.8b | -SEK 5,278,253,176.97 | 63.3x | -34.6x | 6.1x |
| Fri, 08 Mar 2024 | SEK 185.3b | SEK 29.8b | -SEK 5,646,722,587.71 | 57.7x | -32.8x | 6.2x |
| Sun, 04 Feb 2024 | SEK 180.8b | SEK 28.8b | -SEK 5,393,590,879.00 | 61.5x | -33.5x | 6.3x |
| Tue, 02 Jan 2024 | SEK 183.5b | SEK 28.7b | -SEK 1,197,137,927.00 | 61.4x | -153.3x | 6.4x |
| Thu, 30 Nov 2023 | SEK 174.0b | SEK 28.7b | -SEK 1,166,694,268.00 | 56.8x | -149.2x | 6.1x |
| Sat, 28 Oct 2023 | SEK 152.4b | SEK 27.6b | -SEK 1,709,592,305.00 | 43x | -89.2x | 5.5x |
| Mon, 25 Sep 2023 | SEK 161.6b | SEK 27.4b | -SEK 2,020,758,323.00 | 50.2x | -80x | 5.9x |
| Wed, 23 Aug 2023 | SEK 155.2b | SEK 27.6b | -SEK 1,606,736,682.00 | 54.3x | -96.6x | 5.6x |
| Fri, 21 Jul 2023 | SEK 155.9b | SEK 27.5b | -SEK 1,533,093,221.00 | 57.1x | -101.7x | 5.7x |
| Sun, 18 Jun 2023 | SEK 174.7b | SEK 26.4b | -SEK 1,257,284,022.00 | 46.8x | -139x | 6.6x |
| Tue, 16 May 2023 | SEK 175.2b | SEK 26.3b | -SEK 1,377,622,828.00 | 46.2x | -127.2x | 6.7x |
| Thu, 13 Apr 2023 | SEK 173.2b | SEK 25.4b | -SEK 2,028,147,028.00 | 40.7x | -85.4x | 6.8x |
| Sat, 11 Mar 2023 | SEK 168.9b | SEK 25.4b | -SEK 2,020,513,955.00 | 39.2x | -83.6x | 6.7x |
| Mon, 06 Feb 2023 | SEK 176.8b | SEK 24.2b | -SEK 1,769,992,009.00 | 27.8x | -99.9x | 7.3x |
| Wed, 04 Jan 2023 | SEK 162.3b | SEK 23.8b | -SEK 1,842,484,418.00 | 32.2x | -88.1x | 6.8x |
| Fri, 02 Dec 2022 | SEK 162.1b | SEK 23.8b | -SEK 1,732,225,132.00 | 31.8x | -93.6x | 6.8x |
| Sun, 30 Oct 2022 | SEK 149.8b | SEK 23.9b | -SEK 3,207,757,038.00 | 32.8x | -46.7x | 6.3x |
| Tue, 27 Sep 2022 | SEK 135.9b | SEK 22.9b | -SEK 3,319,004,235.00 | 32.3x | -41x | 5.9x |
| Thu, 25 Aug 2022 | SEK 168.3b | SEK 22.6b | -SEK 3,536,838,183.00 | 35.2x | -47.6x | 7.4x |
| Sat, 23 Jul 2022 | SEK 166.9b | SEK 22.6b | -SEK 3,526,919,280.00 | 36.8x | -47.3x | 7.4x |
| Mon, 20 Jun 2022 | SEK 145.2b | SEK 21.4b | -SEK 3,535,551,431.00 | 36.7x | -41.1x | 6.8x |
| Wed, 18 May 2022 | SEK 152.2b | SEK 21.4b | -SEK 3,353,778,988.00 | 42x | -45.4x | 7.1x |
| Fri, 15 Apr 2022 | SEK 176.2b | SEK 19.7b | -SEK 3,200,084,912.00 | 52.8x | -55.1x | 9x |
| Sun, 13 Mar 2022 | SEK 155.2b | SEK 19.6b | -SEK 3,011,263,632.00 | 49.6x | -51.5x | 7.9x |
| Tue, 08 Feb 2022 | SEK 172.7b | SEK 19.1b | -SEK 2,317,096,559.00 | 51.5x | -74.5x | 9x |
Price to Earnings Ratio
-74.5x
Current Industry PE
- Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.7x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 20% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | 1.14% | |
| Healthcare | 3.30% | |
| Biotech | 1.52% | |
| Biotech | 1.52% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SOBI Swedish Orphan Biovitrum | SEK 335.80 | 1.1% +SEK 1.3b | 23.5% | PE32.8x | |
| VITR Vitrolife | SEK 223.40 | 2.5% +SEK 731.1m | 27.1% | PE59x | |
| BIOG B BioGaia | SEK 121.40 | 4.2% +SEK 495.7m | 7.6% | PE36.5x | |
| BONEX Bonesupport Holding | SEK 348.40 | 1.7% +SEK 381.7m | 72.5% | PE253.1x | |
| BIOA B BioArctic | SEK 220.60 | 1.4% +SEK 265.2m | 3.4% | PS116.7x |
